Ligand to split in half, spinning OmniAb platform into its own company

It’s been six years since Ligand Pharmaceuticals plumped down $178 million for OMT and its antibody discovery platform OmniAb. Now, with a slate of big-name partners, it’s time for the technology to take on a new life as its own independent company, Ligand said yesterday.